Optimizing Heart Failure Outcomes by Addressing Iron Deficiency: Managed Care Implications and Considerations in the Emerging Era of Intravenous Iron
This adaptive educational activity is targeted to managed care professionals, physicians, and specialty pharmacists attending the 2021 Academy of Managed Care Pharmacy (AMCP) Annual Meeting. Activity attendees will be given the opportunity to virtually interact with world-renowned expert faculty across all clinically relevant aspects of iron deficiency (ID) management in the setting of comorbid heart failure (HF). The session will begin with a thorough review of the pathophysiologic underpinnings of ID in HF, specifically the role of hepcidin in hyperinflammatory states and the subsequent implications on iron supplementation approaches. The robust prognostic implications and outcomes manifestations of ID in HF, including functional capacity, quality of life, and morbidity and mortality will also be reviewed in detail as a means of providing a foundational knowledge base. In the remainder of the educational session, activity attendees will appraise existing and emerging clinical trial data of IV iron therapies for ID in HF, and then provide a dynamic, case-based opportunity for attendees to apply the information they have learned into real-world clinical scenarios. Lastly, attendees will get to pilot our innovative guidance flowchart as an educational resource and clinical tool for managing ID in HF. All clinical aspects of this presentation will be augmented with cost considerations and implications at every level, allowing for a relevant and impactful educational experience for patient-facing and non-patient-facing clinicians and managed care professionals alike.
This adaptive educational initiative is targeted to managed care pharmacists and pharmacy directors attending the 2021 AMCP virtual meeting.
- Discuss the basic principles of iron metabolism and absorption, with a focus on how these principles apply to treatment.
- Understand the complex pathophysiology underlying iron deficiency (ID), even in the absence of concomitant anemia, with particular emphasis on the role of hepcidin, on heart failure (HF) outcomes and iron supplementation strategies. Recognize the robust impact of comorbid ID and HF, and describe the practical prognostic manifestations of ID on patient functional capacity, quality of life, and morbidity and mortality outcomes.
- Recognize the robust impact of comorbid ID and HF, and describe the practical prognostic manifestations of ID on patient functional capacity, quality of life, and morbidity and mortality outcomes.
- Review the essential utility of serum ferritin and transferrin saturation (TSAT) as diagnostic laboratory indices for ID, and implement the diagnose, treat-to-target, and rapid reassessment cycle into practice.
- Differentiate the practical distinctions between functional and absolute iron deficiency.
- Appraise existing, ongoing, and planned clinical trials of IV iron therapies for ID in HF, and identify pivotal trials that have influenced current practice and consensus guidelines for ID management in HF (ESC and AHA).
Muthiah Vaduganathan, MD, MPH (Activity Chair)
Harvard Medical School
Brigham and Women’s Hospital
Dr. Vaduganathan is a cardiologist at Brigham and Women’s Hospital and Harvard Medical School (Boston, MA) He is interested in drug development and clinical trials of cardiometabolic therapies. He has authored or co-authored more than 275 peer-reviewed publications.
Dr. Vaduganathan serves on the editorial board of the European Journal of Heart Failure and JACC Heart Failure (Social Media/CME Editor). He serves on the ACCF/AHA Task Force on Performance Measures and is a co-chair on an FDA Think Tank on improving future clinical trials in HF. He participates as a Clinical Endpoints Committee member for ongoing advanced-phase trials in HF/post-MI LV dysfunction.
Javed Butler, MD, MPH, MBA
Professor and Chairman, Department of Medicine
University of Mississippi
Javed Butler, MD, MPH, MBA, is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Center in Jackson Mississippi. He is also Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University prior to that.
He received his medical degree from the Aga Khan University and then completed residency training at Yale University, cardiology fellowship and advanced heart failure and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School. He has completed Master of Public Health degree from Harvard University and Master in Business Administration from Emory University.
Dr. Butler is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association. Dr. Butler has authored more than 550 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals. He has been cited numerous times in America’s Best Doctors list.
Katherine E. Di Palo, PharmD, FAHA, FHFSA, BCACP, BCGP
Clinical Program Manager
Hospital Readmissions Reduction Program
Montefiore Medical Center
Assistant Professor of Medicine
Albert Einstein College of Medicine
New York, New York
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.5 contact hours (.15 CEUs) of continuing pharmacy education credit JA0007101-0000-21-003-L01-P.
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™